Dengue Fever Vaccine-various aspects-

There are two authorized dengue vaccines, Dengvaxia (CYD-TDV) and Qdenga (TAK-003), which provide protection against all four serotypes of the dengue virus, but they are not presently accessible in India.

Here’s a more thorough breakdown:

Dengue Vaccines:

Created by Sanofi Pasteur.

Licensed by the U. S. Food and Drug Administration and advised for regular use by the Advisory Committee on Immunization Practices.
Designed for children and adolescents aged 9–16 years who have confirmed past dengue virus infection and reside in regions where dengue is endemic.
Requires three doses, administered 6 months apart.
The manufacturer is halting the production of the vaccine due to insufficient global market demand to sustain its production.
Qdenga (TAK-003):
Developed by Takeda.
A live-attenuated vaccine comprising weakened forms of dengue virus serotypes 1, 2, 3, and 4.
Indicated for dengue disease prevention in those aged 4 and older, according to official guidelines.
Offers protection against fever and hospitalization resulting from dengue disease caused by any of the four dengue virus serotypes.
Butantan-DV:
Another live-attenuated tetravalent dengue vaccine.
Important Considerations:
No Specific Dengue Treatment: There is no specific antiviral treatment available for dengue fever.
Prevention: The most effective way to avoid dengue fever is to prevent mosquito bites.
Dengue-Endemic Areas: Dengue fever is prevalent in numerous tropical and subtropical regions, including certain areas of South and Southeast Asia, Latin America, and Africa.
Travel Precautions: If traveling to a dengue-endemic region, take steps to prevent mosquito bites, such as wearing long sleeves, applying insect repellent, and staying in well-screened or air-conditioned accommodations.
Vaccination: Speak with your healthcare provider to assess if a dengue vaccine is suitable for you, particularly if you live in or plan to travel to a dengue-endemic area.
Current Situation in India: Although there are no licensed vaccines available in India, ICMR and Panacea Biotec have started the first Phase 3 clinical trial for a dengue vaccine.

If Any Patient of ENT Requires Any Surgery, Opd Consultation Or Online Consultation In Clinic of  ENT Specialist Doctor Dr. Sagar Rajkuwar ,He May Contact Him At The Following Address-
Prabha ENT Clinic, Plot no 345,Saigram Colony, Opposite Indoline Furniture Ambad Link Road ,Ambad ,1 km From Pathardi Phata Nashik ,422010 ,Maharashtra, India-Dr. Sagar Rajkuwar (MS-ENT), Cell No- 7387590194, 9892596635

About a Dengue Vaccine

A dengue vaccine offers your child reliable, efficient, and enduring defense against dengue sickness, hospital admission, and severe conditions.
Children must undergo testing to verify any prior dengue infection before receiving the vaccine.
For complete protection, three doses of the vaccine are necessary.
Consult with your child’s healthcare provider to determine if your child qualifies for a dengue vaccine.

Notice regarding Dengvaxia

Sanofi-Pasteur will cease the production of its dengue vaccine for children. The producer is halting the vaccine due to insufficient demand in the worldwide market to sustain its production. The CDC, working with the Puerto Rico Department of Health, will keep informing health professionals about the cessation of Dengvaxia and the recommended use of this vaccine by the Advisory Committee on Immunization Practices (ACIP). Dengvaxia is effective and safe when given as advised. There are two additional dengue vaccines either authorized or in advanced stages of development. Nonetheless, these are not presently accessible in the United States. Individuals can continue to safeguard themselves and their families from dengue by avoiding mosquito bites and managing mosquitoes in and around their residences.

Overview

Dengvaxia is the sole dengue vaccine presently accessible in the United States.
Dengvaxia is advised to avert dengue in youngsters aged 9–16 years, who have a laboratory-confirmed prior dengue virus infection and reside in regions where dengue is prevalent.
Dengue is prevalent in the U. S. territories of American Samoa, Puerto Rico, and the U. S. Virgin Islands, as well as in the freely associated states, which include the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.

For update on further important health related topics and frequently asked questions on health topics by general population please click on the link given below to join our WhatsApp group –

https://chat.whatsapp.com/Lv3NbcguOBS5ow6X9DpMMA

Test prior to vaccination

Laboratory verification of a past dengue infection is necessary for vaccination with Dengvaxia.
Testing prior to vaccination will verify that your child has experienced dengue previously.
In children who have not previously contracted dengue, the dengue vaccine heightens the risk of hospitalization and severe illness if the child contracts dengue after vaccination.
To decrease the risk of vaccinating children who have never experienced dengue, a blood test can determine the presence of a previous dengue infection.
If the test result is affirmative, your child can receive the vaccine.
If the test result is negative, your child will not be eligible for vaccination. Your child should undergo testing again in one or two years.

Types of testing

Your child’s healthcare provider will request a blood test to verify a prior dengue infection. The healthcare provider will request a test that has received approval from the local or territorial health department.

OR

If your child experienced a prior dengue illness that was validated by a specific kind of laboratory test, your child might not require another blood test.

Three doses required

Dose 1 may be administered after verifying that your child had a previous dengue infection.
Dose 2 is administered 6 months following the first dose.
Dose 3 is given 6 months after the second dose.

Safety and efficacy

The dengue vaccine offers protection against all four varieties of dengue.
The vaccine is both safe and effective for children who have had dengue before.
The vaccine has minimal side effects.
The most frequently occurring side effects include tenderness, itchiness, or pain at the injection site, headaches, fatigue, and overall discomfort.
These side effects are typical indications that the body is developing immunity, and they should resolve within a few days.

Special populations

Pregnancy

Pregnant individuals were not specifically included and examined in the vaccine trials. While no notable differences in negative pregnancy results between vaccinated and unvaccinated individuals were identified, the number of pregnant individuals enrolled was insufficient to assess the impact of Dengvaxia on pregnancy.

Is there a vaccine for dengue fever?

Dengvaxia is the sole dengue vaccine presently accessible in the United States. Dengvaxia is advised for preventing dengue in children between the ages of 9 and 16 years, who have a laboratory-confirmed history of dengue virus infection and reside in regions where dengue is prevalent.

How long before travel should you get dengue fever vaccine?

The vaccine provides strong protection after the initial dose, which needs to be administered at least 2 weeks prior to departure. Keep in mind that obtaining the second dose before your upcoming trip to another dengue-endemic area is crucial.

FOR INFORMATION IN GREAT DETAIL ON Dengue Fever Treatments PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.

FOR INFORMATION IN GREAT DETAIL ON Dengue Fever Symptoms PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.

FOR INFORMATION IN GREAT DETAIL ON 7 Warning Signs Of Dengue Fever PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.

FOR INFORMATION IN GREAT DETAIL ON Dengue Breakbone Fever PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.

If Any Patient of ENT Requires Any Surgery, Opd Consultation Or Online Consultation In Clinic of  ENT Specialist Doctor Dr. Sagar Rajkuwar ,He May Contact Him At The Following Address-
Prabha ENT Clinic, Plot no 345,Saigram Colony, Opposite Indoline Furniture Ambad Link Road ,Ambad ,1 km From Pathardi Phata Nashik ,422010 ,Maharashtra, India-Dr. Sagar Rajkuwar (MS-ENT), Cell No- 7387590194, 9892596635

Issued in public interest by –

www.entspecialistinnashik.com